RenovoRx has developed the RenovoCath, which is FDA cleared and now being investigated in an active clinical trial to prove extended median survival and improved quality of life.
The RenovoCath is specifically designed for the targeted delivery of fluids, including diagnostic and therapeutic agents, through a dual-balloon catheter into selected sites in the peripheral vascular system. The proximal and distal occlusion balloons enable effective isolation of the vascular site to allow delivery of chemotherapy in a controlled environment.
The RenovoCath provides a unique approach, using Trans-Arterial Micro-Perfusion (TAMP) to target delivery of an agent directly to the disease site. The RenovoCath TAMP delivery method is being investigated in the TIGeR-PaC clinical study, enrolling newly-diagnosed, locally-advanced pancreatic cancer patients.
Targeted Delivery Works*
Initial data using the RenovoCath has been promising. In one study, 73 percent of patients treated with the RenovoCath had a survival rate of two years. Other studies have found that patients with advanced pancreatic cancer who received chemotherapy via the RenovoCath lived 27.5 months beyond their diagnosis.
Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.
The RenovoRx is cleared for chemotherapeutic drug infusion to selected sites in the peripheral vascular system. Prior to use, please refer to the RenovoRx IFU for complete product indications, warnings, precautions, contraindications, potential adverse effects and detailed instructions for use.